Vanguard S&P 500 ETF (VOO)

Following the closure of the deal, Protect AI's CEO, founders, and employees are expected to join Palo Alto Networks.

HSBC noted that while the market has assumed a significant market share for Eli Lilly, these expectations may be revised in light of potential economic sensitivity to the adoption curve for weight loss drugs.

The $150 billion investment will include more than $30 billion in research and development to advance and continue IBM's American manufacturing of mainframe and quantum computers.

For the full year, Revvity raised its revenue guidance to a range of $2.83 billion to $2.87 billion to reflect recent changes in foreign currency exchange rates.

Domino’s reported a 0.5% drop in same-store sales in the U.S. while international same-store sales rose by about 3.7%.

Bernstein stated that after high Federal Aviation Administration (FAA) scrutiny, Boeing Commercial Airplanes "should be on a much firmer path than in 2023.”

Check out how it compares to an S&P 500 ETF and whether it fits your investing style.

The company now expects the health benefits ratio for the full year to be in the range of 88.9% to 89.5%, up from its previous guidance of 88.4% to 89%.

HCA Healthcare now expects full-year adjusted earnings per share of between $24.05 and $25.85, in line with an estimate of $24.96.

The company’s immunology drugs, Skyrizi and Rinvoq, marked significant revenue growth, offsetting a 50.6% decrease in net revenue from its arthritis drug, Humira.

Revenue increased 16% year-over-year to $4.73 billion but fell short of a Street estimate of $4.86 billion.

The company is eyeing FDA approval for its drug, lenacapavir, for HIV prevention by mid-June.

According to TheFly, JPMorgan expects continued solid search monetization and artificial intelligence innovation in an uncertain macro environment.

United said that the investment includes a path to order up to 100 airplanes and an option for an additional 100.

The company now expects full-year diluted EPS in the range of $6.70 to $7.00, up from its previous guidance of $6.55 to $6.85.

Revenue for the three months through the end of March rose 8% to $1.29 billion, in line with analyst estimates.

Merck estimates that the impact of tariffs implemented to date will result in incremental costs of approximately $200 million.